Mahjoubi Najmeh, Fazeli Ahmad, Dinarvand Rassoul, Khoshayand Mohammad Reza, Shekarchi Maryam, Fazeli Mohammad Reza
Department of Drug and Food Control, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Research and Development Department, Zistdaru Danesh Pharmaceutical Company. Tehran, Iran.
Iran J Pharm Res. 2017 Winter;16(1):103-111.
Liquid protein formulations are prone to form aggregates. The effect of nonionic surfactants such as Polysorbate 20 (PS 20) and n-Dodecyl β-D-maltoside (DDM) on the prevention of aggregation and conformational changes of recombinant human IFNβ-1b (rhIFN β_1b) was explored. Polysorbate has been used in formulations of protein pharmaceuticals. There have been concerns about using PS 20 due to its residual peroxide content which may negatively affect protein efficacy. n-Dodecyl β-D-maltoside has been of interest and shown to be highly effective in prevention of aggregation. Fresh bulk of rhIFN β_1b was formulated using DDM or different concentrations of PS 20. Formulations were exposed to light stress condition according to the ICH guideline of Q1b. The overall conformational integrity of individual samples was characterized by a combination of Circular dichroism (CD), Fluorescence spectroscopy and RP_HPLC techniques. The CD spectrum depicting the conformational integrity of rhIFN β_1b showed 31.9% and 31.2% decreases in α-helix content of protein samples with 0.2% or 0.02% of PS20 compared to only18.2% of that containing 0.2% DDM. The RP-HPLC analysis also showed that the oxidized impurity in formulation containing DDM is less than those contain PS 20. Complementary analysis of the liquid formulations using IFR and UV methods also was in compliance with the data obtained by CD. Compared to PS 20, the sample of rhIFN β_1b formulation with DDM was more resistant to the destruction effect of light. Results were in accordance with previous studies and could suggest DDM as a reliable anti-aggregation surfactant in biopharmaceutical formulations.
液体蛋白质制剂容易形成聚集体。研究了聚山梨酯20(PS 20)和正十二烷基-β-D-麦芽糖苷(DDM)等非离子表面活性剂对重组人干扰素β-1b(rhIFNβ_1b)聚集和构象变化的预防作用。聚山梨酯已用于蛋白质药物制剂中。由于其残留过氧化物含量可能对蛋白质功效产生负面影响,人们对使用PS 20存在担忧。正十二烷基-β-D-麦芽糖苷已受到关注,并显示出在预防聚集方面非常有效。使用DDM或不同浓度的PS 20配制新鲜的大量rhIFNβ_1b。根据ICH Q1b指南,将制剂暴露于光照应激条件下。通过圆二色性(CD)、荧光光谱和反相高效液相色谱(RP_HPLC)技术相结合来表征各个样品的整体构象完整性。描绘rhIFNβ_1b构象完整性的CD光谱显示,与仅含0.2% DDM的蛋白质样品相比,含0.2%或0.02% PS20的蛋白质样品的α-螺旋含量分别下降了31.9%和31.2%。RP-HPLC分析还表明,含DDM的制剂中的氧化杂质比含PS 20的制剂少。使用红外光谱(IFR)和紫外方法对液体制剂进行的补充分析也与CD获得的数据一致。与PS 20相比,含DDM的rhIFNβ_1b制剂样品对光的破坏作用更具抗性。结果与先前的研究一致,表明DDM可作为生物制药制剂中可靠的抗聚集表面活性剂。